<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Pregnant patients have five-fold <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> than no pregnant, and its therapy is mainly with non-fractioned and low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To know clinical characteristics, treatment and perinatal results of <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> associated to pregnancy at Instituto Nacional de Perinatologia </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIAL AND METHODS: Review of the files of patients with diagnosis, prenatal control, and resolution of <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> at Instituto Nacional de Perinatologia </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 45 cases with <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> and pregnancy are described, with: age 29.3 +/- 6 years; gestations, 2.3 +/- 1.2; body mass index, 27.3 +/- 3.5 </plain></SENT>
<SENT sid="4" pm="."><plain>Risk factors: peripheral <z:hpo ids='HP_0005293'>venous insufficiency</z:hpo>, 17 (37.8%); <z:hpo ids='HP_0001513'>obesity</z:hpo>, 11 (24.4%); previous <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo>, 10 (22.2%); <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, 2 (4.4%); and <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e>, 1 (2.2%) </plain></SENT>
<SENT sid="5" pm="."><plain>Diagnosis by gestational age: first trimester 10 (22%), second trimester 18 (40%), third trimester 15 (34%), and puerperium 2 (4%) </plain></SENT>
<SENT sid="6" pm="."><plain>Affected pelvic member: left, 32 (71%); right, 12 (27%); bilateral, 1 (2%) </plain></SENT>
<SENT sid="7" pm="."><plain>Initial treatment was always with non-fractionated <z:chebi fb="5" ids="28304">heparin</z:chebi>, and prevention of recurrence was made with acenocumarin in 41 cases (93%), and with non-fractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> in 4 (7%) </plain></SENT>
<SENT sid="8" pm="."><plain>Resolution of pregnancy was 38.1 +/- 2 weeks of gestation: vaginal delivery, 18 cases (40%); cesarean, 27 (60%) </plain></SENT>
<SENT sid="9" pm="."><plain>Weight at birth was 3,026 +/- 464 g, with Apgar score &lt; 6 in one case </plain></SENT>
<SENT sid="10" pm="."><plain>In four cases there were four therapy-derived complications (3 with echymosis and <z:hpo ids='HP_0000421'>epistaxis</z:hpo> and 1 with macroscopic <z:hpo ids='HP_0000790'>hematuria</z:hpo>) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Timely and appropriate therapy of <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> during pregnancy prevents thromboembolic complications, and generally is associated to satisfactory maternal and fetal results </plain></SENT>
</text></document>